OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Week of Mar. 26, 2012: Catalent Completes UK Expansion; Novasep Opens New Facility in China; and More
Catalent Completes UK Expansion; Novasep Opens New Facility in China; and More.
Abbott has announced that AbbVie will be the name of the new, independent research-based pharmaceutical company it expects to launch by the end of 2012. The naming of the new company is the latest milestone in the process that began in October 2011, when Abbott announced it would separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. AbbVie will include Abbott’s current portfolio of proprietary pharmaceuticals and biologics. Read More
Catalent Pharma Solutions has completed its new development and analytical solutions’ laboratories at its facility in Swindon, United Kingdom. From this new laboratory suite, Catalent will offer analytical testing, development support, and regulatory services to pharmaceutical and biopharmaceutical companies. The laboratory suite incorporates expanded facilities for the storage and testing of controlled and cytotoxic substances. Catalent’s new Swindon laboratories offer a comprehensive range of development and analytical services. These services include European import testing, qualified person and regulatory consulting services, methods development, and microbial, sterility, and stability testing for a range of advanced-dose forms, including for inhaled and orally administered substances. Read More
Novasep, a supplier of manufacturing solutions to the life-sciences industries, has opened a new 2000-m2 (21,527.820 ft2) facility in Shanghai, China. The site is intended to increase Novasep’s process-development and engineering capabilities to meet increasing Chinese and East Asian demand. The facilities will also add to Novasep’s existing 12 global synthesis and process sites in the US, France, Germany, Belgium, and the Bahamas. Read More
Industry Briefs:
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More
